Medtronic’s Extravascular ICD Hits Targets In Trial; Will Soon Compete With Boston Scientific’s S-ICD
Results from the pivotal trial of Medtronic’s EV ICD extravascular ICD, presented at the European Society of Cardiology congress in Barcelona, imply that Medtronic will be able to launch the device in Europe by the end of this year and in the US in 2023.
You may also be interested in...
Exec Chat: Abbott Bets On Modular And Leadless Devices To Be The Future Of Cardiac Rhythm Management
Medtech Insight interviewed Leonard Ganz, a veteran cardiac electrophysiologist who recently joined Abbott’s cardiac rhythm management business as its divisional vice president of medical affairs and chief medical officer.
The MODULAR ATP clinical trial has begun to enroll patients to evaluate the safety, performance and effectiveness of Boston Scientific’s mCRM modular therapy system, which includes the Emblem MRI S-ICD and the Empower MPS leadless pacemaker.
In a 21-patient first in-human pilot trial, Medtronic’s Extravascular Implantable Cardioverter Defibrillator (EV ICD) system successfully terminated induced ventricular arrhythmias in 89.5% of patients and achieved pacing capture in 95% of patients.